Dalba Got Back? Use of Dalbavancin for the Treatment of Vertebral Osteomyelitis.
Open Forum Infect Dis
; 11(3): ofae070, 2024 Mar.
Article
em En
| MEDLINE
| ID: mdl-38449918
ABSTRACT
Data evaluating dalbavancin use for vertebral osteomyelitis remain limited. In our retrospective cohort, 29 of 34 (85.3%) patients completed their dalbavancin course. Adverse reactions occurred for 6 (17.6%) and infection recurrence in 3 (8.8%) within 90 days. Dalbavancin appears to be safe and well-tolerated for vertebral osteomyelitis.
Texto completo:
1
Base de dados:
MEDLINE
Idioma:
En
Ano de publicação:
2024
Tipo de documento:
Article